Volume 133, Issue 1



January 3, 2019 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Cover Figure: Review Series: iron metabolism and its disorders. See the articles in the series.

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
In this plenary paper, DiNardo and colleagues present early-clinical-phase data on the safety and efficacy of the BCL-2 inhibitor venetoclax combined with hypomethylating agents for remission induction in older individuals with acute myeloid leukemia.

Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease
The investigators present a novel therapeutic strategy for chronic graft-versus-host disease (cGVHD) and demonstrate that a small-molecule inhibitor is able to reverse lung injury due to experimental cGVHD by targeting B-cell lymphoma 6 (BCL6), a transcriptional regulator of T follicular helper cells and germinal center B cells.

Targeted inhibition of PI3Kα/δ is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL
This study presents thorough experimental evidence demonstrating that targeted therapy with the combination of PI3Kα/δ inhibition (copanlisib) and BCL-2 blockade (venetoclax) is synergistic in B-cell receptor–dependent diffuse large B-cell lymphomas (DLBCL) with molecular features of BCL-2 dysregulation.

Introduction to a review series on iron metabolism and its disorders
The five articles in this review series offer comprehensive insights into the landscape of emerging research in iron metabolism and the clinical management of patients with iron disorders.

The articles in this review series include the following:

View this week's complete table of contents

Why Submit to Blood?


Blood (, the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (, the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.